Related references
Note: Only part of the references are listed.Are we choosing wisely for inflammatory bowel disease care? The IG-IBD choosing wisely campaign
Marco Vincenzo Lenti et al.
DIGESTIVE AND LIVER DISEASE (2020)
Induction and maintenance treatment of inflammatory bowel disease: A comprehensive review
Dong Yeon Jeong et al.
AUTOIMMUNITY REVIEWS (2019)
Unmet Medical Needs in Ulcerative Colitis: An Expert Group Consensus
Silvio Danese et al.
DIGESTIVE DISEASES (2019)
Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn's Disease
Mark Lowenberg et al.
GASTROENTEROLOGY (2019)
Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis
B. E. Sands et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Healthcare Providers Underestimate Patients' Glucocorticoid Use in Crohn's Disease
Subrata Ghosh et al.
DIGESTIVE DISEASES AND SCIENCES (2019)
ACG Clinical Guideline: Ulcerative Colitis in Adults
David T. Rubin et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2019)
Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience
Ferdinando D'Amico et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2019)
ACG Clinical Guideline: Management of Crohn's Disease in Adults
Gary R. Lichtenstein et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2018)
Physicians' Perspectives on Cost, Safety, and Perceived Efficacy Determine Aminosalicylate Use in Crohn's Disease
Christopher Ma et al.
DIGESTIVE DISEASES AND SCIENCES (2018)
Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's Disease
Paul Rutgeerts et al.
GASTROENTEROLOGY (2018)
Modified Delphi Process for the Development of Choosing Wisely for Inflammatory Bowel Disease
Geoffrey C. Nguyen et al.
INFLAMMATORY BOWEL DISEASES (2017)
A multi-centre audit of excess steroid use in 1176 patients with inflammatory bowel disease
C. P. Selinger et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2017)
Incidence, Prevention and Management of Anti-Drug Antibodies Against Therapeutic Antibodies in Inflammatory Bowel Disease: A Practical Overview
Pieter Hindryckx et al.
DRUGS (2017)
Treatment satisfaction, preferences and perception gaps between patients and physicians in the ulcerative colitis CARES study: A real world-based study
Laurent Peyrin-Biroulet et al.
DIGESTIVE AND LIVER DISEASE (2016)
Long-term side effects of glucocorticoids
Merih Oray et al.
EXPERT OPINION ON DRUG SAFETY (2016)
Prevalence of Inflammatory Bowel Disease Among Adults Aged ≥18 Years - United States, 2015
James M. Dahlhamer et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2016)
Corticosteroid Use and Complications in a US Inflammatory Bowel Disease Cohort
Akbar K. Waljee et al.
PLOS ONE (2016)
Comparative Immunogenicity of TNF Inhibitors: Impact on Clinical Efficacy and Tolerability in the Management of Autoimmune Diseases. A Systematic Review and Meta-Analysis
Sarah S. Thomas et al.
BIODRUGS (2015)
IBD and health-related quality of life - Discovering the true impact
Sanna Lonnfors et al.
JOURNAL OF CROHNS & COLITIS (2014)
Review article: immunogenicity of anti-TNF biologics in IBD - the role of patient, product and prescriber factors
A. C. Moss et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2013)
Perception gaps between patients with ulcerative colitis and healthcare professionals: an online survey
Stefan Schreiber et al.
BMC GASTROENTEROLOGY (2012)
Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis
William J. Sandborn et al.
GASTROENTEROLOGY (2012)
Treatment of inflammatory bowel disease (IBD)
Anand B. Pithadia et al.
PHARMACOLOGICAL REPORTS (2011)
Impact of Ulcerative Colitis from Patients' and Physicians' Perspectives: Results from the UC: NORMAL Survey
David T. Rubin et al.
INFLAMMATORY BOWEL DISEASES (2009)
Infliximab for induction and maintenance therapy for ulcerative colitis
P Rutgeerts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Communicating with patients with inflammatory bowel disease
A Husain et al.
INFLAMMATORY BOWEL DISEASES (2004)
Share Paper
